Try a new search

Format these results:

Searched for:

All

Total Results:

532595


How power is conceptualized and operationalized in evidence-based intervention implementation: a scoping review

Ramanadhan, Shoba; Cruz, Jennifer L; Safaeinili, Nadia; Alexander, Savannah; Lee, Matthew; Jeon, Elaine D; Adsul, Prajakta; Shelton, Rachel C; Stanton, Megan
BACKGROUND:The potential for implementation science (IS) to address health inequities is limited by insufficient attention to power. Although the field emphasizes context, it remains unclear how best to examine and intervene on power relations related to the implementation of evidence-based interventions (EBIs). This scoping review aimed to determine: 1) To what extent do research projects studying EBI implementation explicitly examine power? 2) In these studies, how is power conceptualized, defined, operationalized, and understood? 3) What opportunities exist to examine and intervene upon power through IS research? METHODS:Following established procedures, we undertook a six-step process: 1) articulating research question and purpose; 2) identifying relevant studies; 3) selecting studies; 4) extracting data; 5) summarizing data; and 6) reporting results. We characterized studies' attention to power using Fung's power framework, which attends to everyday, policy, structural, and ethical power. Based on publications available as of February 2022, we included English-language EBI implementation studies from clinical, community, and public health settings that explicitly attended to power. Data extraction included study context, IS frameworks used, definitions and measures of power, and characterizations of how power influenced implementation processes and outcomes. RESULTS:Of 3,531 articles screened, 28 papers explicitly discussed power in relation to EBI implementation and 11 presented a formal definition of power. Most studies explored everyday and structural power, with far less attention to policy power and almost none to ethical power. Conceptualizations and operationalizations of power varied widely, and few studies reported grounding in IS frameworks. Explicit strategies to intervene upon power were limited. Most studies focused on short-term integration goals, with limited discussion of how power dynamics shape what counts as evidence, whose interests are served, or opportunities for systems transformation. CONCLUSIONS:Researchers have the opportunity to explicitly integrate power theories and frameworks into conceptual models for IS studies to reshape IS efforts and build this evidence base. This will allow the field to move towards critical, systems-focused perspectives that examine how power shapes and can be used to reshape the evidence base, implementation systems, implementation strategies, and implementation, health, and system outcomes.
PMID: 42231438
ISSN: 1748-5908
CID: 6043872

Race, oxygen exposure, and retinopathy of prematurity: re-examining a persistent epidemiologic paradox

Zhou, Beryl; Rodriguez, Sarah H; Warren, Alexis; Skondra, Dimitra
Retinopathy of prematurity (ROP) is a leading cause of childhood blindness that arises from disrupted retinal vascular development in premature infants. Oxygen exposure remains a central driver of treatment-warranted ROP, as higher saturation levels suppress early retinal vascular growth and later promote pathological neovascularization. Large, randomized trials of oxygen targeting show that lower oxygen saturation ranges reduce the incidence of treatment-requiring ROP, though with trade-offs in mortality. Observational cohorts, including the CRYO-ROP, ETROP, and e-ROP trials, consistently report lower rates of treatment-warranted ROP and reduced treatment need among Black infants despite similar or greater prematurity risk. Multiple explanations have been proposed to account for the paradoxically lower rates of treatment-warranted ROP observed among Black infants. Although biologic variations in angiogenic pathways have been proposed, evidence suggests that structural and clinical factors may offer an alternative explanation for these patterns. Black race is strongly correlated with residence in neighborhoods with greater socioeconomic disadvantage, which is associated with increased risk of prematurity and missed ROP follow-up visits. In addition, pulse oximeters may overestimate oxygen saturation in individuals with darker skin pigmentation, potentially altering targeted oxygen exposure. Survival-related selection bias may further contribute to this paradox, as infants at the highest risk of both mortality and treatment-warranted ROP may not survive long enough to develop treatment-requiring disease. This review examines racial differences in ROP severity and examines how oxygen exposure and structural factors may contribute to these disparities, while acknowledging the limited evidence supporting biologic explanations.
PMCID:13222856
PMID: 42232597
ISSN: 1535-3699
CID: 6043972

An examination of the influence of prefrontal cortical brain stimulation on sexual decision making

Shaw, Michael T; Cingranelli, Leah; Kobryn, Simona; Tavarez, Isabella; Torres-Aragón, Alberto; Balderrama-Durbin, Christina M; Gibb, Brandon E; Charvet, Leigh E; Mattson, Richard E
The goal of this study was to clarify the contribution of prefrontal cortex activity to men's appraisals, affect states, and decision making in the context of hypothetical heterosexual dating scenarios lacking clear consent. Transcranial direct stimulation (tDCS) was applied to the prefrontal cortex to examine whether it would modify and reduce the likelihood of hypothetical dating violence. Participants (n = 102) responded to first-person vignettes wherein a woman responded either ambiguously or with a refusal to their sexual advance. While responding to the vignettes, participants received sham or active tDCS to modulate prefrontal cortex-mediated responding. Neuromodulation interacted with the communication response type of the woman in the vignette (e.g. ambiguous vs. refusal responses) to influence participants' reports of negative affect (F = 9.57, P = 0.002, Cohen's f2
PMCID:13225266
PMID: 42232253
ISSN: 2753-149x
CID: 6043932

Brain Imaging Findings Show Efficacy of Fetal Endoscopic Third Ventriculostomy as Prenatal Treatment for Induced Congenital Hydrocephalus in Fetal Lambs

Duru, Soner; Oria, Marc; Fernandez-Tome, Blanca; Peiro, Lucas; Encinas, Jose L; Sanchez-Margallo, Francisco M; Peiro, Jose L
BACKGROUND AND OBJECTIVES/OBJECTIVE:Congenital obstructive hydrocephalus (HCP) causes progressive, irreversible fetal brain damage through ventricular enlargement and increasing fetal cerebral tissue compression. Postnatal treatments of choice include ventriculoperitoneal shunting or endoscopic third ventriculostomy (ETV). Intrauterine treatments, such as ventriculoamniotic shunting, were attempted unsuccessfully 4 decades ago and failed to improve postnatal outcomes, likely due to inadequate fetal patient selection. The aim of this study was to evaluate the efficacy of prenatal ETV for early ventricular decompression and potential prevention of fetal brain damage in hydrocephalic fetal lambs. METHODS:HCP was induced in 24 fetal lambs by injecting BioGlue into the cisterna magna at E85. Three weeks later (E105-110), fetal ETV was successfully performed on 8 fetuses using a small rigid cystoscope. Fetal brain lateral ventricular diameters and cerebral mantle thicknesses were monitored by prenatal and postnatal ultrasounds and fetal MRI. RESULTS:According to the Cincinnati HCP Severity Scale, moderate and severe HCP subgroups responded positively to fetal ETV with reduced cerebral ventricular diameters. Ten days post-ETV, severe HCP fetal lambs improved to moderate levels, whereas those with moderate HCP normalized by birth. A similar improvement pattern was seen for the mechanical compression threshold (ventricular diameters/biparietal diameter). Biparietal diameter values did not significantly differ among nontreated, treated, and normal control groups during pregnancy. MRI revealed a significant increase in brain mantle thickness in the prenatally treated fetuses. CONCLUSION/CONCLUSIONS:Prenatal ETV is feasible in hydrocephalic fetal lambs and effectively reverses ventriculomegaly and brain compression in cases of severe or moderate fetal HCP in this ovine model.
PMCID:12875635
PMID: 40844280
ISSN: 1524-4040
CID: 6043132

Focal Cryo-ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer

Lepor, Herbert; Fiske, Jared; Tafa, Majlinda; Pirraglia, Elizabeth; Wysock, James S
OBJECTIVE:To report 7-year oncological outcomes of focal cryo-ablation (FCA) for focal intermediate favorable risk prostate cancer (IFRPCa). PATIENTS AND METHODS/METHODS:Beginning March 2017, all men with focal IFRPCa undergoing FCA meeting the following eligibility criteria were enrolled in our longitudinal prospective study: a single MRI PIRADS 2-5 target concordant with unilateral IFRPCa, no gross extra-prostatic extension or very distal apical disease on MRI, and no Grade Group (GG) ≥2 contralateral to the MRI target. The oncological surveillance protocol included PSA testing every 6 months, and MRI testing at 6-12 months, 2, 3.5, 5.0, and 7.5 years. Prostate biopsy was performed for rising PSA, suspicious MRI's or at the discretion of the surgeons. The main outcome measure was clinically significant prostate cancer (csPCa) recurrence. RESULTS:276 men were enrolled in the study. Overall, 39 (14.1%) developed a csPCa recurrence. Baseline mean PSA was significantly greater in subjects developing csPCa recurrence. There were no prostate cancer mortalities and 3 (0.01%) developed metastasis. The csPCa recurrence free survival at 3, 5 and 7 years was 90.20%, 78.36%, and 70.31%, respectively. African American race was the only significant independent predictor for developing a csPCa recurrence. Compliance with protocol MRI at 7.5 years was 90.9%. CONCLUSIONS:The present study supports FCA as a treatment option for focal IFRPCa associated with an MRI target with no evidence of extra-capsular extension or distal apical disease on MRI, and no contralateral GG> 1 disease.
PMID: 42229815
ISSN: 1527-9995
CID: 6043832

Assessing HPV Vaccination Trends and Their Alignment with Evolving Recommendations

Loheide, Sarah E; Lee, Braydon M; Taufique, Zahrah M; Moses, Lindsey E
OBJECTIVE:HPV vaccination recommendations have expanded to include both sexes and a broadened age range since approval in 2006. These changes and increasing HPV-related head and neck cancer rates support vaccination of older and male patients, necessitating changes in HPV education. We aim to analyze vaccination trends and to identify opportunities for increasing awareness. STUDY DESIGN/METHODS:Cross-sectional study analyzing vaccination trends between 2007 and 2023. SETTING/METHODS:US hospitals and clinics using Epic. METHODS:Using Epic Cosmos, a national database, vaccination trends for patients aged 9 to 45 were stratified by year, demographics, and administering provider specialty. RESULTS:19.6 million HPV vaccinations were administered between 2007 and 2023. The inclusion of males aged 9 to 21 in the recommendations beginning in 2009 corresponded with an 836% increase in vaccinations in this group from 2010 to 2016. Males comprised 49.9% of vaccinated patients aged 9 to 18 in 2023, a percentage that increased annually since 2010. Head and neck cancer prevention became a designated vaccine indication in 2020. Despite broadened indications, total vaccination declined by 47.1% from 2016 to 2023 in patients aged 9 to 26. In 2012, 74.8% of vaccinations were administered in pediatrics and 18.3% in family medicine. In 2023, pediatrics administered 46.6%, family medicine 33.3%, OBGYN 7.1%, and primary care 6.8%. CONCLUSION/CONCLUSIONS:Expanding guidelines have had inconsistent impacts on vaccination trends, as rates decreased in target populations since 2016. Males contribute equally to pediatric but not adult vaccinations. Departments administering vaccines are diversifying, though pediatrics predominates. Gendered and outdated education and marketing could contribute to disparities and discordance with guidelines.
PMID: 42233631
ISSN: 1097-6817
CID: 6044022

The Global Consensus on Keratoconus 2: From Definitions to Decision Making

Hafezi, Farhad; Gomes, José Álvaro Pereira; Hillen, Mark; Ambrósio, Renato
PMID: 42228626
ISSN: 1536-4798
CID: 6043772

Denosumab versus bisphosphonates for the management of bone metastases originating from breast cancer: a systematic review and meta-analysis

Boutros, Marc; Awad, Guy; Saad, Jean-Pierre; Mitri, Maria; Masrouha, Karim
BACKGROUND/UNASSIGNED:Bone metastases from breast cancer cause skeletal-related events (SREs), including pain, fractures, and the need for radiation or surgery. Denosumab and bisphosphonates (BP) reduce these complications, but their relative efficacy and safety remain unclear. METHODS/UNASSIGNED:PubMed, Scopus, Cochrane Library, and Google Scholar were searched through October 2025. Five publications (four unique studies: three randomized trials and one retrospective cohort) were included. Sensitivity analyses were limited to randomized trials when feasible. Outcomes included SRE incidence and skeletal endpoints, plus renal, metabolic, hematologic, musculoskeletal, gastrointestinal, infectious adverse events, osteonecrosis of the jaw (ONJ), and serious, grade ≥ 3, and treatment-related events. RESULTS/UNASSIGNED: = 0.04) were reduced. Other outcomes, including uNTx, ONJ, serious and grade ≥ 3 events, thrombocytopenia, infectious, gastrointestinal, and respiratory events, were comparable. Results were consistent in randomized-only analyses. CONCLUSION/UNASSIGNED:In breast cancer patients with bone metastases, denosumab may benefit those at higher risk of renal toxicity or skeletal complications, while treatment decisions should remain individualized. PROTOCOL REGISTRATION/UNASSIGNED:www.crd.york.ac.uk/PROSPERO identifier is CRD420251231881.
PMID: 42227119
ISSN: 1744-8301
CID: 6043672

Stratification and accumulation? Explaining changing mortality inequities between business owners and non-owners in the U.S. (1984-2022)

Eisenberg-Guyot, Jerzy; Prins, Seth J; Minh, Anita; Hajat, Anjum; Renson, Audrey
BACKGROUND:Given established relationships between social class and mortality, the growing concentration of income, wealth, and power among business owners in the U.S. may have increased mortality inequities across classes. To investigate this hypothesis, we analyzed temporal changes in mortality inequities between owners and non-owners. METHODS:Our sample included respondents ages 25-64 in the 1984, 1989, 1994, and 1999-2013 Panel Study of Income Dynamics with mortality follow-up through 2022 (respondents: 22,103; observations: 103,965). Business owners were individuals with personal or family ownership of, or direct financial interest in, a business in the prior year. Using g-computation, we estimated how inequities between owners and non-owners in 10-year age-adjusted mortality risks changed from 1984-2013. Next, we analyzed whether any changes were attributable to shifting social stratification. Finally, we analyzed whether growing income and wealth disparities between owners and non-owners exacerbated inequities. RESULTS:In 1984, non-owners had 1.4 times (95% CI: 1.1, 1.8) greater 10-year age-adjusted mortality risks than owners. In 2013, the figure was 2.3 (95% CI: 1.8, 3.0), yielding a ratio of risk ratios (RRR) of 1.7 (95% CI: 1.1, 2.5). After social-stratification-adjustment, within-year inequities lessened; however, increases across years attenuated only somewhat (2013 vs 1984 RRR: 1.5 [95% CI: 0.99, 2.2]). Finally, we did not find that increases in inequities across years would have lessened if income and wealth distributions had remained at 1984 levels. CONCLUSIONS:Mortality inequities between owners and non-owners have increased and cannot be fully explained by social stratification and individual-level income and wealth distributions.
PMID: 42223287
ISSN: 1531-5487
CID: 6043512

Charting the decline of the fourth wave: US overdose deaths by race, ethnicity and substance involvement

Friedman, Joseph R; Palamar, Joseph J; Ciccarone, Daniel; Gaines, Tommi L; Borquez, Annick; Shover, Chelsea L; Strathdee, Steffanie A
AIMS/OBJECTIVE:To characterize decreases in overdose death rates in the United States (US) between 2023 and 2024 by race/ethnicity, and substance involvement. DESIGN/METHODS:Population-based study of national death records accessed via the Centers for Disease Control and Prevention (CDC) Wide-ranging ONline Data for Epidemiologic Research (WONDER) platform using an underlying cause of death approach. SETTING/METHODS:US. PARTICIPANTS/CASES/METHODS:All individuals who died from drug overdose between January 1999 and December 2024. MEASUREMENTS/METHODS:Annual overdose deaths per 100 000 population. Year of occurrence of overdose death, substance involvement, race/ethnicity of decedents. FINDINGS/RESULTS:After many years of increases, the US overdose death rate dropped 24.4% between 2023 and 2024. Decreases reflected declining illicit fentanyl-involved deaths (with and without stimulant involvement). The fourth wave of the US overdose crisis-defined by deaths involving fentanyl together with stimulants-declined for the first time in 2024. Despite overall decreases, deaths involving stimulants without fentanyl and deaths involving xylazine continued to represent a growing fraction of overdose fatalities. Non-Hispanic Black and African Americans had the largest decrease in death rates in 2023-2024, falling by 29.3% but remaining elevated at 36.0 per 100 000, 1.51 times higher than the national average of 23.7 per 100 000. Non-Hispanic American Indian and Alaska Native individuals had the highest overdose death rates rate in 2024, at 50.8 per 100 000, 2.15 times the national average rate, and experienced a below-average relative decrease of 20.1%. CONCLUSIONS:All four previously defined waves of the US overdose crisis appear to be in decline, as deaths involving illicit fentanyl, with and without stimulants, dropped sharply between 2023 and 2024. Concurrently, the fraction of overdose deaths involving stimulants without fentanyl and those involving xylazine continued to increase. While racial disparities in drug overdose death rates narrowed slightly during this period, large gaps remain, with the highest overdose death rates among American Indian, Alaska Native, and Black individuals.
PMID: 42227062
ISSN: 1360-0443
CID: 6043662